Go Pro
→ Beginner’s Guide to Gold (From Goldco Direct, LLC) (Ad)tc pixel Free TEVA Stock Alerts

Teva Pharmaceutical Industries (TEVA) Competitors

Teva Pharmaceutical Industries logo
$35.34 -0.02 (-0.06%)
As of 01:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

TEVA vs. PFE, BMY, GSK, SNY, and TAK

Should you buy Teva Pharmaceutical Industries stock or one of its competitors? MarketBeat compares Teva Pharmaceutical Industries with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Teva Pharmaceutical Industries include Pfizer (PFE), Bristol Myers Squibb (BMY), GSK (GSK), Sanofi (SNY), and Takeda Pharmaceutical (TAK). These companies are all part of the "pharmaceuticals" industry.

How does Teva Pharmaceutical Industries compare to Pfizer?

Teva Pharmaceutical Industries (NYSE:TEVA) and Pfizer (NYSE:PFE) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 0.6% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Pfizer had 61 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 73 mentions for Pfizer and 12 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 1.36 beat Pfizer's score of 0.45 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
9 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Pfizer
24 Very Positive mention(s)
11 Positive mention(s)
25 Neutral mention(s)
10 Negative mention(s)
1 Very Negative mention(s)
Neutral

Teva Pharmaceutical Industries currently has a consensus target price of $42.00, suggesting a potential upside of 18.85%. Pfizer has a consensus target price of $28.28, suggesting a potential upside of 4.30%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Pfizer.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90
Pfizer
2 Sell rating(s)
14 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.19

Teva Pharmaceutical Industries has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Pfizer has higher revenue and earnings than Teva Pharmaceutical Industries. Pfizer is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$17.26B2.39$1.41B$0.6058.90
Pfizer$62.58B2.47$7.77B$0.7635.67

Pfizer has a net margin of 6.80% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Pfizer's return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries4.08% 32.64% 6.34%
Pfizer 6.80%19.63%8.46%

Summary

Pfizer beats Teva Pharmaceutical Industries on 10 of the 17 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Bristol Myers Squibb?

Teva Pharmaceutical Industries (NYSE:TEVA) and Bristol Myers Squibb (NYSE:BMY) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Teva Pharmaceutical Industries presently has a consensus price target of $42.00, suggesting a potential upside of 18.85%. Bristol Myers Squibb has a consensus price target of $66.06, suggesting a potential upside of 1.51%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Bristol Myers Squibb.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90
Bristol Myers Squibb
1 Sell rating(s)
11 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.52

Teva Pharmaceutical Industries has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

In the previous week, Bristol Myers Squibb had 24 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 36 mentions for Bristol Myers Squibb and 12 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 1.36 beat Bristol Myers Squibb's score of 0.41 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
9 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Bristol Myers Squibb
11 Very Positive mention(s)
6 Positive mention(s)
16 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Bristol Myers Squibb has higher revenue and earnings than Teva Pharmaceutical Industries. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$17.26B2.39$1.41B$0.6058.90
Bristol Myers Squibb$49.19B2.70$7.05B$4.5414.33

Bristol Myers Squibb has a net margin of 18.87% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Bristol Myers Squibb's return on equity of 66.90% beat Teva Pharmaceutical Industries' return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries4.08% 32.64% 6.34%
Bristol Myers Squibb 18.87%66.90%14.74%

Summary

Bristol Myers Squibb beats Teva Pharmaceutical Industries on 11 of the 17 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to GSK?

GSK (NYSE:GSK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

15.7% of GSK shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

GSK presently has a consensus price target of $53.00, indicating a potential upside of 1.95%. Teva Pharmaceutical Industries has a consensus price target of $42.00, indicating a potential upside of 18.85%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than GSK.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GSK
2 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.10
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

GSK has higher revenue and earnings than Teva Pharmaceutical Industries. GSK is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GSK$43.07B2.44$7.54B$3.2016.25
Teva Pharmaceutical Industries$17.26B2.39$1.41B$0.6058.90

GSK has a net margin of 14.56% compared to Teva Pharmaceutical Industries' net margin of 4.08%. GSK's return on equity of 43.23% beat Teva Pharmaceutical Industries' return on equity.

Company Net Margins Return on Equity Return on Assets
GSK14.56% 43.23% 11.60%
Teva Pharmaceutical Industries 4.08%32.64%6.34%

GSK has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 9 more articles in the media than GSK. MarketBeat recorded 12 mentions for Teva Pharmaceutical Industries and 3 mentions for GSK. Teva Pharmaceutical Industries' average media sentiment score of 1.36 beat GSK's score of 0.73 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GSK
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Teva Pharmaceutical Industries
9 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

GSK beats Teva Pharmaceutical Industries on 9 of the 17 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Sanofi?

Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi (NASDAQ:SNY) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Sanofi has a net margin of 8.66% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Sanofi's return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries4.08% 32.64% 6.34%
Sanofi 8.66%14.19%7.95%

Sanofi has higher revenue and earnings than Teva Pharmaceutical Industries. Sanofi is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$17.26B2.39$1.41B$0.6058.90
Sanofi$49.35B2.14$8.84B$1.9122.84

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Teva Pharmaceutical Industries presently has a consensus price target of $42.00, indicating a potential upside of 18.85%. Sanofi has a consensus price target of $49.50, indicating a potential upside of 13.49%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, research analysts plainly believe Teva Pharmaceutical Industries is more favorable than Sanofi.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90
Sanofi
1 Sell rating(s)
9 Hold rating(s)
3 Buy rating(s)
2 Strong Buy rating(s)
2.40

In the previous week, Teva Pharmaceutical Industries had 3 more articles in the media than Sanofi. MarketBeat recorded 12 mentions for Teva Pharmaceutical Industries and 9 mentions for Sanofi. Teva Pharmaceutical Industries' average media sentiment score of 1.36 beat Sanofi's score of 0.56 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
9 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Sanofi
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Teva Pharmaceutical Industries has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

Summary

Teva Pharmaceutical Industries beats Sanofi on 10 of the 17 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Takeda Pharmaceutical?

Teva Pharmaceutical Industries (NYSE:TEVA) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

In the previous week, Teva Pharmaceutical Industries had 5 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 12 mentions for Teva Pharmaceutical Industries and 7 mentions for Takeda Pharmaceutical. Teva Pharmaceutical Industries' average media sentiment score of 1.36 beat Takeda Pharmaceutical's score of 1.27 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
9 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Takeda Pharmaceutical
5 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Teva Pharmaceutical Industries has higher earnings, but lower revenue than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$17.26B2.39$1.41B$0.6058.90
Takeda Pharmaceutical$28.32B1.98-$1.01B$0.3451.51

Teva Pharmaceutical Industries has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.08, indicating that its stock price is 108% less volatile than the broader market.

Teva Pharmaceutical Industries currently has a consensus price target of $42.00, suggesting a potential upside of 18.85%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, research analysts clearly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90
Takeda Pharmaceutical
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Teva Pharmaceutical Industries has a net margin of 4.08% compared to Takeda Pharmaceutical's net margin of 3.80%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Takeda Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries4.08% 32.64% 6.34%
Takeda Pharmaceutical 3.80%10.95%5.34%

Summary

Teva Pharmaceutical Industries beats Takeda Pharmaceutical on 15 of the 16 factors compared between the two stocks.

Get Teva Pharmaceutical Industries News Delivered to You Automatically

Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TEVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TEVA vs. The Competition

Export
MetricTeva Pharmaceutical IndustriesPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$41.14B$11.92B$7.04B$24.20B
Dividend YieldN/A2.69%2.58%3.69%
P/E Ratio58.84788.54269.9729.10
Price / Sales2.39967.38650.6613.69
Price / Cash9.4815.1228.8919.37
Price / Book5.1410.3311.264.91
Net Income$1.41B$2.77B$3.45B$1.06B
7 Day Performance2.77%1.99%3.62%1.36%
1 Month Performance7.67%-1.56%-0.56%2.35%
1 Year Performance116.28%191.17%77.38%20.17%

Teva Pharmaceutical Industries Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TEVA
Teva Pharmaceutical Industries
4.2416 of 5 stars		$35.34
-0.1%		$42.00
+18.8%		+116.0%$41.14B$17.26B58.8433,950
PFE
Pfizer
3.6649 of 5 stars		$25.05
+0.2%		$28.50
+13.8%		+8.7%$142.54B$62.58B19.1275,000
BMY
Bristol Myers Squibb
4.1028 of 5 stars		$65.45
+0.2%		$63.59
-2.8%		+40.6%$133.37B$49.19B14.4232,500
GSK
GSK
2.9623 of 5 stars		$51.52
-0.3%		$53.00
+2.9%		+40.6%$104.55B$43.07B16.1166,841
SNY
Sanofi
3.1627 of 5 stars		$42.95
-0.3%		$49.50
+15.3%		-7.8%$104.44B$49.35B22.4974,846

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:TEVA) was last updated on 8/10/2026 by MarketBeat.com Staff.
From Our Partners
FDA Clears This Under-$5 Biotech for Phase 2 Clinical Trial
A NASDAQ-listed biotech just cleared a major FDA milestone. Its lead therapy, Lucid-MS, has been cleared for P...
The Tomorrow Investor | Sponsoredtc pixel
SpaceX is NOT the #1 IPO of 2026
A lesser known AI company is growing faster than both SpaceX and OpenAI. Its coding business reportedly grew f...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
If your money lives inside one bank, pay close attention. On December 1st, 2025, a Congressional committee pub...
Decentralized Masters | Sponsoredtc pixel
This Junior Silver Explorer Is Closing In on Its Biggest Catalyst
A past-producing Nevada silver project holds a historical 36 million ounce silver-equivalent resource, plus mo...
Wall Street Logic | Sponsoredtc pixel